Study of family connections in blood and lymph cancers
Official title: Genetic Epidemiology of Lymphoproliferative Disorders
Run by Mayo Clinic · NCT00626496 · Data updated 2026-11-12
This study looks at families with multiple members diagnosed with blood and lymph cancers to see if genetics and environmental factors play a role in their development.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | April 1, 2004 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | November 2, 2026 |
| Trial ID | NCT00626496 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are families with at least two living blood relatives diagnosed with a lymphoproliferative disorder.
✕Probably not a fit
Patients without a family history of lymphoproliferative disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the genetic and environmental factors that may contribute to the development of blood and lymph cancers, such as lymphoma and leukemia, which often show familial clustering. By examining families with multiple affected members, researchers aim to identify patterns and potential risk factors associated with these disorders. Participants will include families with at least two living blood relatives diagnosed with a lymphoproliferative disorder. The study will collect data on family history and environmental exposures to better understand the etiology of these cancers.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of the risk factors for blood and lymph cancers, potentially guiding prevention and early detection strategies.
How similar studies have gone: Other studies have shown success in understanding familial patterns in cancer, suggesting that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
At least 2 living, blood related relatives, affected with a lymphoproliferative disorder.
Where it's running
-
Mayo Clinic
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Susan Slager, Ph.D. — Mayo Clinic
- Study coordinator: Catie Erding
- Email: Erding.Catherine@mayo.edu
- Phone: 1-855-899-0693
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas
A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.
-
Early palliative care for patients with multiple myeloma and aggressive lymphoma
This study is testing if early palliative care can improve the quality of life and comfort for people with multiple myeloma and aggressive lymphoma while they receive their usual cancer treatment.
-
Early heart function check after CAR-T treatment
We will test whether people treated with CAR‑T cells for blood cancers have early changes in heart function by doing an ultrasound and blood tests 3–5 days after infusion.
-
Treatment of B-cell malignancies with ALETA-001
This study is testing a new treatment called ALETA-001 to see if it can help people with relapsed non-Hodgkin lymphoma who didn't respond well to previous therapies.
-
CAR-T therapy outcomes and quality of life in older adults with B‑cell lymphoma
This project will see how CAR‑T therapy affects older adults (age 60+) with relapsed or refractory B‑cell lymphomas, focusing on daily function and quality of life while they receive standard care.
-
Targeted therapy for advanced cancers based on genetic profiling
This study is testing whether targeted treatments based on the genetic makeup of advanced cancers can help patients with conditions like non-Hodgkin lymphoma and multiple myeloma feel better and have more effective options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.